PHARMACEUTICAL COMPOSITION FOR RADIATION THERAPY OF EGFR-TKI-RESISTANT LUNG CANCER CAUSED BY PTEN FUNCTION DEFICIENCY

摘要

The present invention provides a pharmaceutical composition for radiation therapy of epithelial growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistant lung cancer caused by PTEN function deficiency, which includes a mammalian target of rapamycin (mTOR) inhibitor as a radiosensitizer or pharmaceutically acceptable salts thereof, solvate, or hydrate.;COPYRIGHT KIPO 2014;[Reference numerals] (AA,CC) Cell survival rate (% against control group); (BB) rapamycin (nM); (DD) Administration amount of radiation (Gy)